Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab versus omalizumab in severe chronic rhinosinusitis with nasal polyps and comorbid asthma
2021-000829-27Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Dupilumab arm with Omalizumab arm (2 arms). Started Jun 2021; status: completed.
02
Drugs
dupilumabomalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2021-000829-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000829-27.